Results 211 to 220 of about 3,662,534 (344)
Review: James McHugh, An Unholy Brew: Alcohol in Indian History and Religions
History of Science in South Asia, 2023 Vitus Angermeier
doaj +1 more source
Osteoarchaeology and the History of Medicine in our experience. [PDF]
Acta Biomed, 2019 Iorio S, Badino P, Gorini I, Aliverti M.
europepmc +1 more source
Molecular Oncology, EarlyView.In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková +14 more
wiley +1 more source
[The "Plague Doctor's Mask" in the German Museum for the History of Medicine, Ingolstadt]. [PDF]
NTM, 2020 Ruisinger MM.
europepmc +1 more source
Molecular Oncology, EarlyView.In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim +11 more
wiley +1 more source
[Oral History in Medicine and Narrative Medicine - a Commentary on the Question of Vulnerability]. [PDF]
NTMArp A.
europepmc +1 more source
Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management
Molecular Oncology, EarlyView.DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez +5 more
wiley +1 more source